Home Dementias Unexpected worst parts of post-surgery recovery : braincancer

Unexpected worst parts of post-surgery recovery : braincancer

I am about 6 weeks post-op for supratotal resection of grade 2 oligodendroglioma in my right frontal lobe – nearly half the right frontal lobe was removed, if you exclude the motor regions. Only a small chunk of my pre-motor cortex was scooped out. Everything was way easier than I expected – had no deficits or change in cognition what so ever, refused painkillers to give my liver and kidneys a break and just toughed out the pain for a few days. It was pretty much like a constant nasty ache just on the side of my head they cut open, or occasionally random shooting pains elsewhere, slept ok despite this. They sent me home after only about 4 days, since I was recovering fast. Had one string of seizures a day after coming home, no more since.

I haven’t really had many complaints compared to what most people probably experience, but I’ll tell what personally has been bugging me the most….

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments